Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Bone targeted antimicrobials for the treatment of diabetic foot related infections and osteomyelitis

Award Number: R43AR073727
ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2018
PERIOD OF PERFORMANCE END DATE: 06/30/2021

Group Awards By:

View Award Description

Bone targeted antimicrobials for the treatment of diabetic foot related infections and osteomyelitis - ABSTRACT Diabetes Mellitus is a serious chronic disease in which the physiological homeostatic controls in the body becomes less responsive to changing blood glucose levels. In Type II diabetes the body makes little or no insulin (the hormone responsible for reducing blood glucose levels) or the mechanisms down stream of insulin become unresponsive to the insulin produced. Type II diabetes is the most prevalent form of the disease accounting for over 90% of the >20 million people in the US with the disease. Diabetic peripheral neuropathy is one of the primary complications of diabetes, and up to 50% of diabetic patients will present with this issue. This leads to problems with cutaneous wound healing and to ulcerations and advanced infections particularly in the foot. Diabetic Foot Infections (DFI) and associated diabetic foot osteomyelitis (DFO) are serious infections which can lead to very high levels of sequelae including amputation. The DFO infections are complex and difficult to treat bone infections often requiring long-term antibiotic treatment and surgery.! Here we lay out a potential therapeutic solution to this problem based on the use of bisphosphonate (BP)-antimicrobial conjugates that will target to bone and release their antimicrobial payload at the bone surface. Our strategy will directly target the bacterial biofilm reservoir on the bone and lower the amount of systemic drug treatment needed, limiting extra-osseous exposure. Our preliminary results support testing the feasibility of using this highly innovative strategy for the treatment of DFO. To support establishing the feasibility of this approach we set out three specific aims: 1) we will synthesize novel drug candidates based on an advanced newer generation fluoroquinolone, moxifloxacin (MOXI), including several linkage strategies to tune the bone target and release kinetics, 2) we will test these BP-MOXI conjugates in vitro using hydroxyapatite bone mineral models of biofilm infections, and 3) we will test the conjugate with the most favorable release kinetics and bactericidal activity (from aim two) in a type II diabetic mouse model of osteomyelitis. There is a great unmet medical need for novel and effective treatments for DFO, and we believe that our novel and innovative BP-MOXI conjugate, that is capable of releasing MOXI directly into the site of bone infection, will provide a transformative treatment for this disease. Here we lay out the strategy to prove the feasibility of this approach. !


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2018	BIOVINC, LLC	1421 STATE ST STE B	SANTA BARBARA	CA	93101	SANTA BARBARA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	12/1/2021	NEW	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2018	BIOVINC, LLC	1421 STATE ST STE B	SANTA BARBARA	CA	93101	SANTA BARBARA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	6/4/2020	NEW	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $225,000 )
2018	2018	BIOVINC, LLC	1421 STATE ST STE B	SANTA BARBARA	CA	93101	SANTA BARBARA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	6/12/2018	NEW	$225,000
														Subtotal = $225,000

Grand Total All Awards = $225,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Bone targeted antimicrobials for the treatment of diabetic foot related infections and osteomyelitis

Award Number: R43AR073727

ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2018

PERIOD OF PERFORMANCE END DATE: 06/30/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer